Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma

[1]  Dongsheng Yu,et al.  Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma. , 2012, Oral oncology.

[2]  R. Berkowitz,et al.  Dysregulation of microRNA‐204 mediates migration and invasion of endometrial cancer by regulating FOXC1 , 2012, International journal of cancer.

[3]  L. Tanoue.  Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .

[4]  P. Zhang,et al.  MicroRNA-99a Inhibits Hepatocellular Carcinoma Growth and Correlates with Prognosis of Patients with Hepatocellular Carcinoma* , 2011, The Journal of Biological Chemistry.

[5]  H. Feilotter,et al.  The MicroRNA-200 Family Is Upregulated in Endometrial Carcinoma , 2011, PloS one.

[6]  H. Mackay,et al.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Danish Sayed,et al.  MicroRNAs in development and disease. , 2011, Physiological reviews.

[8]  S. Lewin.  Revised FIGO staging system for endometrial cancer. , 2011, Clinical obstetrics and gynecology.

[9]  A. Blann,et al.  Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006 , 2011, British Journal of Cancer.

[10]  Masahiko Kuroda,et al.  Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma , 2011, PloS one.

[11]  Ankit Malhotra,et al.  miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. , 2011, Cancer research.

[12]  Thomas Tuschl,et al.  miRNAs in human cancer , 2011, The Journal of pathology.

[13]  Robert E. Brown,et al.  Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. , 2011, International journal of clinical and experimental pathology.

[14]  Seong-Rim Kim,et al.  Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[15]  Y. Yoshida,et al.  Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer. , 2010, European journal of cancer.

[16]  R. Broaddus,et al.  A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.

[17]  Muller Fabbri,et al.  Comprehensive miRNA profiling of surgically staged endometrial cancer. , 2010, American journal of obstetrics and gynecology.

[18]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[19]  Y. Nagakawa,et al.  Deregulation of miR‐92a expression is implicated in hepatocellular carcinoma development , 2010, Pathology international.

[20]  Muneesh Tewari,et al.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.

[21]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[22]  Martin M Matzuk,et al.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. , 2010, Molecular endocrinology.

[23]  Vinod Scaria,et al.  Consensus miRNA expression profiles derived from interplatform normalization of microarray data. , 2010, RNA.

[24]  K. Griffith,et al.  Expression of metabolically targeted biomarkers in endometrial carcinoma. , 2010, Gynecologic oncology.

[25]  N. Park,et al.  Expression of mTOR protein and its clinical significance in endometrial cancer. , 2009, Medical science monitor : international medical journal of experimental and clinical research.

[26]  M. Kudo,et al.  Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients , 2009, PloS one.

[27]  P. Northcott,et al.  MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma , 2009, PloS one.

[28]  Zhongqiu Lin,et al.  Expression profile of mammalian microRNAs in endometrioid adenocarcinoma , 2009, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[29]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[30]  R. Wenham,et al.  The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[31]  Hansjuerg Alder,et al.  The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. , 2009, Gynecologic oncology.

[32]  Michael Karin,et al.  p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling , 2009, Cell.

[33]  W. Weichert,et al.  Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro , 2009, Journal of Cancer Research and Clinical Oncology.

[34]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[35]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[36]  R. Broaddus,et al.  Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma , 2008, Clinical Cancer Research.

[37]  Heidi J. Peltier,et al.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. , 2008, RNA.

[38]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[39]  Lan Xiao 肖 兰,et al.  The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].

[40]  S. Kyo,et al.  Concomitant activation of AKT with extracellular‐regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss , 2007, Cancer science.

[41]  Linda Wong.  Endogenous Controls for Real-Time Quantitation of miRNA Using TaqMan® MicroRNA Assays , 2007 .

[42]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[43]  Yu Liang,et al.  BMC Genomics , 2007 .

[44]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  G. Mortier,et al.  qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.

[46]  X. Matías-Guiu,et al.  PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. , 2006, Human pathology.

[47]  A. Gadducci,et al.  Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. , 2006, Critical reviews in oncology/hematology.

[48]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[49]  Soma Das,et al.  Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. , 2004, International Journal of Oncology.

[50]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[51]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[52]  C. Tokunaga,et al.  mTOR integrates amino acid- and energy-sensing pathways. , 2004, Biochemical and biophysical research communications.

[53]  J. Herman,et al.  Abnormalities of E‐ and P‐cadherin and catenin (β‐, γ‐catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia , 2003 .

[54]  J. Herman,et al.  Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. , 2003, The Journal of pathology.

[55]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[56]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[57]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[58]  C. Eng,et al.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. , 2000, Journal of the National Cancer Institute.

[59]  H. Bonnefoi,et al.  Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  A. Sakurada,et al.  PTEN1 is frequently mutated in primary endometrial carcinomas , 1997, Nature Genetics.

[61]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[62]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.